Skip to main content

Table 1 Baseline Characteristics of All Participants

From: The relationship between SARS-COV-2 RNA positive duration and the risk of recurrent positive

 

Non-recurrent positive

Recurrent positive

P value

No. of patients

170

241

 

Sex

 Female

81 (47.65%)

121 (50.21%)

0.609

 Male

89 (52.35%)

120 (49.79%)

Age, Median (IQR), year

47.00 (35.00–61.00)

50.00 (38.00–63.00)

0.023

BMI, Mean (SD), kg/m2

22.93 (3.24)

22.98 (4.35)

0.894

SPD, Median (IQR), day

16.50 (12.00–24.00)

20.00 (13.00–29.00)

0.020

Routine blood test

 WBC, Mean (SD), × 109/L

5.37 (1.89)

6.22 (2.69)

< 0.001

 NC, Median (IQR), × 109/L

2.86 (2.15–3.91)

3.10 (2.36–4.18)

0.163

 NP, Mean (SD), %

58.69 (12.60)

54.90 (17.74)

0.017

 LC, Median (IQR), × 109/L

1.34 (1.00–1.80)

1.63 (1.24–2.12)

< 0.001

 LP, Mean (SD), %

29.73 (11.86)

31.71 (14.66)

0.146

 MC, Median (IQR), × 109/L

0.49 (0.39–0.63)

0.43 (0.34–0.56)

0.005

 MP, Median (IQR), %

9.75 (7.53–12.50)

7.40 (6.10–9.40)

< 0.001

 Hemoglobin, Mean (SD), g/L

130.98 (16.20)

128.03 (21.38)

0.130

 PLT, Mean (SD), × 109/L

203.06 (66.38)

219.19 (74.74)

0.025

Clinical type

 Mild

7 (4.12%)

22 (9.13%)

0.141

 Moderate

141 (82.94%)

179 (74.27%)

 Severe

17 (10.00%)

32 (13.28%)

 Critical

5 (2.94%)

8 (3.32%)

Underlying disease

 No. of chronic diseases

  0

123 (72.35%)

139 (57.68%)

0.002

  1

35 (20.59%)

65 (26.97%)

  2

12 (7.06%)

21 (8.71%)

  3

0 (0.00%)

12 (4.98%)

  4

0 (0.00%)

4 (1.66%)

 Hypertension

  No

144 (84.71%)

191 (79.25%)

0.161

  Yes

26 (15.29%)

50 (20.75%)

 Diabetes

  No

157 (92.35%)

218 (90.46%)

0.503

  Yes

13 (7.65%)

23 (9.54%)

 CHD

  No

166 (97.65%)

227 (94.19%)

0.092

  Yes

4 (2.35%)

14 (5.81%)

 CPD

  No

165 (97.06%)

225 (93.36%)

0.094

  Yes

5 (2.94%)

16 (6.64%)

 CKD

  No

168 (98.82%)

238 (98.76%)

0.95

  Yes

2 (1.18%)

3 (1.24%)

 CLD

  No

162 (95.29%)

203 (84.23%)

< 0.001

  Yes

8 (4.71%)

38 (15.77%)

 Malignant tumor

  No

168 (98.82%)

236 (97.93%)

0.705

  Yes

2 (1.18%)

5 (2.07%)

Treatment

 No. of antiviral drugs

  0

32 (18.82%)

46 (19.09%)

0.001

  1

72 (42.35%)

106 (43.98%)

  2

47 (27.65%)

84 (34.85%)

  3

19 (11.18%)

5 (2.07%)

 Glucocorticoid

  No

143 (84.12%)

223 (92.53%)

0.007

  Yes

27 (15.88%)

18 (7.47%)

  1. Data presented as mean and standard deviation (Gaussian distribution, compared with student t-test) or median and quartile (Skewed distribution, compared with Kruskal–Wallis analysis) for continuous variables; number and percentage for categorical variables (Chi-square or Fisher’s exact tests)
  2. Clinical type, routine blood test and treatment were the conditions of previous discharge
  3. CPD included COPD, tuberculosis, asthma, and idiopathic pulmonary fibrosis. CLD included chronic hepatitis B, chronic hepatitis C, nonalcoholic steatohepatitis, autoimmune liver disease and cirrhosis. Antiviral drugs include Favipiravir, Oseltamivir, Chloroquine/Hydroxychloroquine, Lopinavir–Ritonavir, Remdesivir and Arbidol
  4. SD standard deviation, CHD coronary heart disease, CPD chronic pulmonary disease, CKD chronic kidney disease, CLD chronic liver disease, WBC white blood cell count, NC neutrophil count, NP neutrophil percentage, LC lymphocyte count, LP lymphocyte percentage, MC monocyte count, MP monocyte percentage, PLT platelet count, SPD SARS-CoV-2 RNA positive duration